Breadcrumb Navigation

Merkelzellkarzinom: A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study

Stadium/Indikation inkl. Kurzinfo

Merkelzellkarzinom

MCC nach Progress unter Immuntherapie mit antiPD1

Anti-PDL1 und Domatinostat

Kurztitel

MERKLIN 2 study
NCT04393753

Offizieller Titel

A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study

PI (Principal Investigator)

Prof. Reinhard Dummer

Zuständige Ärztin

Fabienne Fröhlich

Tel. +41 43 253 25 13

Behandelnder Fachbereich

Dermatologische Klinik